Riina-Minna Väänänen1, Hans Lilja2, Leni Kauko3, Pauliina Helo3, Henna Kekki3, Angel M Cronin4, Andrew J Vickers5, Martti Nurmi6, Kalle Alanen7, Anders Bjartell8, Kim Pettersson3. 1. Department of Biotechnology, University of Turku, Turku, Finland. Electronic address: riina-minna.vaananen@utu.fi. 2. Departments of Laboratory Medicine, Surgery (Urology), and Medicine (GU-Oncology), Memorial Sloan-Kettering Cancer Center, New York, NY; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom; Institute of Biomedical Technology, University of Tampere, Tampere, Finland; Department of Laboratory Medicine, Lund University, Skåne University Hospital, Malmö, Sweden. 3. Department of Biotechnology, University of Turku, Turku, Finland. 4. Center for Outcomes and Policy Research, Dana-Farber Cancer Institute, Boston, MA. 5. Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY. 6. Department of Surgery, Turku University Hospital, Turku, Finland. 7. Department of Pathology, Turku University Hospital, Turku, Finland. 8. Department of Clinical Sciences, Division of Urological Cancers, Lund University, Skåne University Hospital, Malmö, Sweden.
Abstract
OBJECTIVE: To investigate whether messenger ribonucleic acid (mRNA) expression of TMPRSS2-ERG fusion gene, a suggested prostate cancer (PCa) biomarker, was specific to cancerous lesions alone and to study the expression of SPINK1 and PCA3 mRNAs in the same cohort to also explore the proposed mutual exclusivity of TMPRSS2-ERG and SPINK1 expression. METHODS: Levels of 2 TMPRSS2-ERG transcripts, PCA3, and SPINK1 mRNAs were measured with highly standardized reverse transcription quantitative polymerase chain reaction assays in cystoprostatectomy specimens from 19 patients with invasive bladder cancer and 174 radical prostatectomy (RP) samples (88 histologically benign prostate [HBP] tissues and 86 from cancerous lesions) from 87 patients with clinically localized PCa. RESULTS: Expression of TMPRSS2-ERG transcripts was detected in 45 of 88 (51%) HBP tissues from RP specimens and more frequently (57 of 86, 66%) found in cancerous lesions. In contrast, TMPRSS2-ERG expression was detected in only 2 of 19 (11%) cystoprostatectomy specimens, both with incidental PCa foci elsewhere in the gland. Similar trends of changes in the expression of PCA3 and SPINK1 were present in HBP tissue from RP compared with cystoprostatectomy specimens. CONCLUSION: Although the expression of TMPRSS2-ERG, SPINK1, and PCA3 mRNA is higher or more frequently found in cancerous lesions, HBP tissues from patients with clinically localized PCa manifest molecular, mRNA level changes that are absent in cystoprostatectomy specimens lacking incidental PCa foci or infrequent in cystoprostatectomy specimens containing incidental PCa. If this finding is replicated, these molecular assays could be used to inform men with negative biopsy results about the likelihood of cancerous lesions in unsampled regions and hence the need for repeat biopsy.
OBJECTIVE: To investigate whether messenger ribonucleic acid (mRNA) expression of TMPRSS2-ERG fusion gene, a suggested prostate cancer (PCa) biomarker, was specific to cancerous lesions alone and to study the expression of SPINK1 and PCA3 mRNAs in the same cohort to also explore the proposed mutual exclusivity of TMPRSS2-ERG and SPINK1 expression. METHODS: Levels of 2 TMPRSS2-ERG transcripts, PCA3, and SPINK1 mRNAs were measured with highly standardized reverse transcription quantitative polymerase chain reaction assays in cystoprostatectomy specimens from 19 patients with invasive bladder cancer and 174 radical prostatectomy (RP) samples (88 histologically benign prostate [HBP] tissues and 86 from cancerous lesions) from 87 patients with clinically localized PCa. RESULTS: Expression of TMPRSS2-ERG transcripts was detected in 45 of 88 (51%) HBP tissues from RP specimens and more frequently (57 of 86, 66%) found in cancerous lesions. In contrast, TMPRSS2-ERG expression was detected in only 2 of 19 (11%) cystoprostatectomy specimens, both with incidental PCa foci elsewhere in the gland. Similar trends of changes in the expression of PCA3 and SPINK1 were present in HBP tissue from RP compared with cystoprostatectomy specimens. CONCLUSION: Although the expression of TMPRSS2-ERG, SPINK1, and PCA3 mRNA is higher or more frequently found in cancerous lesions, HBP tissues from patients with clinically localized PCa manifest molecular, mRNA level changes that are absent in cystoprostatectomy specimens lacking incidental PCa foci or infrequent in cystoprostatectomy specimens containing incidental PCa. If this finding is replicated, these molecular assays could be used to inform men with negative biopsy results about the likelihood of cancerous lesions in unsampled regions and hence the need for repeat biopsy.
Authors: Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan Journal: Science Date: 2005-10-28 Impact factor: 47.728
Authors: M J Bussemakers; A van Bokhoven; G W Verhaegh; F P Smit; H F Karthaus; J A Schalken; F M Debruyne; N Ru; W B Isaacs Journal: Cancer Res Date: 1999-12-01 Impact factor: 12.701
Authors: Yan Ping Yu; Douglas Landsittel; Ling Jing; Joel Nelson; Baoguo Ren; Lijun Liu; Courtney McDonald; Ryan Thomas; Rajiv Dhir; Sydney Finkelstein; George Michalopoulos; Michael Becich; Jian-Hua Luo Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: Daphne Hessels; Jacqueline M T Klein Gunnewiek; Inge van Oort; Herbert F M Karthaus; Geert J L van Leenders; Bianca van Balken; Lambertus A Kiemeney; J Alfred Witjes; Jack A Schalken Journal: Eur Urol Date: 2003-07 Impact factor: 20.096
Authors: S Velaeti; E Dimitriadis; K Kontogianni-Katsarou; A Savvani; E Sdrolia; G Pantazi; S Stefanakis; T Trangas; N Pandis; K Petraki Journal: Tumour Biol Date: 2014-06-25
Authors: Danyelle Winchester; Luisel Ricks-Santi; Tshela Mason; Muneer Abbas; Robert L Copeland; Desta Beyene; Emmanuel Y Jingwi; Georgia M Dunston; Yasmine M Kanaan Journal: Anticancer Res Date: 2015-07 Impact factor: 2.480
Authors: Marianne Schmid; Quoc-Dien Trinh; Markus Graefen; Margit Fisch; Felix K Chun; Jens Hansen Journal: World J Urol Date: 2014-05-14 Impact factor: 4.226
Authors: Mesude Bicak; Katharina Lückerath; Teja Kalidindi; Michael E Phelps; Sven-Erik Strand; Michael J Morris; Caius G Radu; Robert Damoiseaux; Mari T Peltola; Norbert Peekhaus; Austin Ho; Darren Veach; Ann-Christin Malmborg Hager; Steven M Larson; Hans Lilja; Michael R McDevitt; Robert J Klein; David Ulmert Journal: Proc Natl Acad Sci U S A Date: 2020-06-12 Impact factor: 11.205
Authors: Igor Brikun; Deborah Nusskern; Daniel Gillen; Amy Lynn; Daniel Murtagh; John Feczko; William G Nelson; Diha Freije Journal: Biomark Res Date: 2014-12-12
Authors: Radka Stoyanova; Alan Pollack; Mandeep Takhar; Charles Lynne; Nestor Parra; Lucia L C Lam; Mohammed Alshalalfa; Christine Buerki; Rosa Castillo; Merce Jorda; Hussam Al-Deen Ashab; Oleksandr N Kryvenko; Sanoj Punnen; Dipen J Parekh; Matthew C Abramowitz; Robert J Gillies; Elai Davicioni; Nicholas Erho; Adrian Ishkanian Journal: Oncotarget Date: 2016-08-16